|
Title
|
Published
|
Price
|
By
GlobalData
Banyan Biomarkers (Banyan) is a research and development company. It develops and markets biomarker diagnostic tests for the healthcare markets. Banyan creates point of care blood test to diagnose traumatic brain injury. The company offers biomarkers
|
May
2013
|
$
750
|
By
Wildwood Ventures Ltd
The Biomarker Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012. Using these reports,
|
January
2013
|
$
1495
|
By
GlobalData
US Biomarkers, Inc. (US Biomarkers) is a biomarkers developer. It has a proprietary platform for development of blood-based biomarkers using disease-specific epigenetic changes. The company develops biomarkers for detection, diagnosis and monitoring
|
December
2012
|
$
750
|
By
GlobalData
BioMarker Strategies, LLC (BioMarker Strategies) is a tissue-based cancer diagnostics company. The company''s product SnapPath, a novel automated tumor biopsy processing and testing system, is used to quickly test and analyze a patient’s live solid tu
|
December
2012
|
$
750
|
By
GlobalData
BioMarker Strategies is a cancer diagnostics company. The company''s product SnapPat, a novel automated tumor biopsy processing and testing system, is used to quickly test and analyze a patient’s live solid tumor sample at the point of biopsy.BioMar
|
August
2012
|
$
250
|
By
GlobalData
ACS Biomarker is a phramaceutical and healthcare company engaged in the discovery and development biomarkers that help in improving prognosis and management of cardiac disease. The company is based in Maastricht, Netherlands.ACS Biomarker - Medical
|
August
2012
|
$
250
|
By
GlobalData
Banyan Biomarkers (Banyan) is principally engaged in the development and marketing of biomarker diagnostic tests for the in-vitro diagnostic markets. It offers analytical services such as assessment for decision making. The company is focused on dev
|
October
2011
|
$
750
|
By
GlobalData
This report is a source for data, analysis and actionable intelligence on the Toscana Biomarkers Srl portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informat...
|
March
2011
|
$
750
|
By
ICON Group International, Inc.
This econometric study covers the world outlook for cardiac biomarkers across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (...
|
January
2011
|
$
795
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for cardiac biomarkers across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, C...
|
January
2011
|
$
495
|
By
Espicom Limited
Few would contest the need for pharmaceutical research to be productive. Despite significant increases in the cost of drug discovery and drug development, the number of new NCE and biological products reaching the market has not improved. A...
|
August
2010
|
$
1215
|
By
Life Science Analytics
contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stage...
|
July
2010
|
$
750
|
By
Espicom Limited
Part of Espicom's new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the cancer biomarker sector, along with a critical assessment of the companies involved.
|
August
2008
|
$
1040
|
By
Espicom Limited
Part of Espicom's new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the cardiovascular biomarker sector, along with a critical assessment of the companies involved.
|
August
2008
|
$
1040
|
By
Espicom Limited
Part of Espicom's new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the CNS biomarker sector, along with a critical assessment of the companies involved.
|
August
2008
|
$
1040
|